NEW YORK – Transcend Therapeutics, a biotechnology company that develops medicines to treat neuropsychiatric diseases, including post-traumatic stress disorder (PTSD), has recently closed a Series A funding round of $40 million. Led by Alpha Wave Global and Integrated Investment Partners, this funding round will enable Transcend to launch multiple clinical trials, including a phase II study, with its next-generation psychoactive compound. Transcend has raised nearly $42 million to date.
Transcend Therapeutics, which was founded in 2021 and incubated by leading early-stage venture studio AlleyCorp, develops next-generation psychoactive drugs aiming to benefit the more than 50 million Americans who suffer from neuropsychiatric diseases. While various psychedelics have demonstrated promise for the treatment of PTSD, Transcend focuses on a psychoactive compound that may be more accessible for the tens of millions of patients in need. Its lead compound, methylone (TSND-201), has short-acting and mild psychological effects, and thus likely requires less clinician time than other psychedelic compounds. Methylone has the potential to be used as an adjunctive treatment to existing pharmacotherapies (e.g. SSRIs), making it better suited to integrate into the existing psychiatric paradigm and healthcare infrastructure.
The Transcend leadership team has extensive experience across the full drug development lifecycle, leading to pivotal contributions on 13 FDA-approved drugs totaling $7 billion dollars in M&A and public company value. The leadership team includes:
“Mental health diseases are one of the leading causes of disability in the United States and globally, yet available treatments are ineffective for many patients, can take weeks to kick in, and frequently have chronic side effects. At Transcend, we’re working to change that, starting by bringing a next-generation compound, methylone, to market as a potential rapid-acting, disease-modifying, non-hallucinogenic treatment for neuropsychiatric conditions like PTSD,” Transcend Therapeutics Co-Founder and CEO Blake Mandell said. “In a published clinical case series, methylone has demonstrated robust responses in patients with PTSD. This funding will enable us to more rapidly enter clinical trials, and ultimately make this – and other – life-changing medicine available to those in need.”
The Series A round was also supported by Global Founders Capital and Emerald Development Managers, among others.
NEW YORK -- Arbol, a climate risk solutions provider operating in over 15 countries, has closed…
NEW YORK -- Ticket marketplace StubHub has launched its inaugural WNBA Season Preview, revealing the top-selling…
Amtrak, in conjunction with the Massachusetts Department of Transportation (MassDOT) and New York State Department…
Governor Kathy Hochul and U.S. Senate Majority Leader Charles Schumer announced the start of construction…
NEW YORK -- Audience measurement firm Nielsen has released their latest Diverse Intelligence Series report…
NEW YORK -- At its annual gala dinner last week, Conservation International honored Amazon founder…